Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells
- R. Safaei, Barrett J. Larson, S. Howell
- Biology, ChemistryMolecular Cancer Therapeutics
- 1 October 2005
This study shows that the lysosomal compartment of human ovarian carcinoma cells selected for stable resistance to CDDP is markedly reduced in size, and that these cells abnormally sort some lysOSomal proteins and the putative CDDP transporters into an exosomal pathway that also exports CDDP.
Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells
A small increase in ATP7A expression produced resistance to all three of the clinically available Pt drugs, and there are substantial differences between Cu and the Pt drugs with respect to how they interact with ATP6A and the mechanism by which ATP7a protects the cell.
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
- M. Glantz, K. Jaeckle, S. Howell
- MedicineClinical cancer research : an official journal of…
- 1 November 1999
In patients with solid tumor neoplastic meningitis, DepoCyt produced a response rate comparable to that of methotrexate and significantly increased the time to neurological progression while offering the benefit of a less demanding dose schedule.
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
There was no difference in the response rates between the treatment arms as a function of residual disease, and both regimens were well tolerated with comparable hematologic and nonhematologic toxicity.
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer
Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin
Therefore, whereas CTR1 controls the cellular accumulation of all three drugs at low concentrations, accumulation of L-OHP is not dependent on CTR1 at higher concentrations, and is a substrate for some other cellular entry mechanism consistent with its different clinical spectrum of activity.
Intraperitoneal cisplatin with systemic thiosulfate protection.
Regression of intraperitoneal tumor masses was observed in patients with far-advanced ovarian carcinoma, mesothelioma, and malignant carcinoid, and even at doses up to 270 mg/m2, no local toxicity occurred.
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.
- M. Glantz, S. LaFollette, S. Howell
- Medicine, BiologyJournal of clinical oncology : official journal…
- 1 October 1999
DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
The major copper influx transporter, copper transporter 1 (CTR1), has now been shown to control the tumor cell accumulation and cytotoxic effect of cisplatin, carboplatin, and oxaliplatin.